Affinage

Showing DNAJB11 — ERDJ3 is a alias.

DNAJB11

DnaJ homolog subfamily B member 11 · UniProt Q9UBS4

Length
358 aa
Mass
40.5 kDa
Annotated
2026-06-09
31 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DNAJB11 (ERdj3/HEDJ) is a luminal, ER-resident HSP40 co-chaperone that orchestrates folding triage in the ER lumen by directly capturing unfolded substrates and handing them to the Hsp70 chaperone BiP (PMID:10827079, PMID:15525676). Its J domain interacts with BiP in an ATP-dependent manner and stimulates BiP's ATPase activity (PMID:10827079); substrate binding occurs independently of BiP through conserved residues in domains I and II, with ERdj3 engaging clients first to prevent aggregation and then dissociating before folding completes (PMID:15525676, PMID:19090675). Substrate release is mechanistically coupled to BiP's catalytic cycle—both physical contact and ATP hydrolysis by BiP are required, and only one protomer of the assembly need stimulate BiP ATPase for release (PMID:18923428, PMID:25143379). Self-assembly is central to function: ERdj3 forms a native tetramer (dimer of dimers) through inter-subunit contacts in domains II and III, and dimerization is strictly required for substrate binding (PMID:19090675, PMID:28655754). ER retention and enhanced chaperone activity depend on forming a complex with SDF2/SDF2L1, in which two SDF2L1 molecules incorporate into the ERdj3 dimer and which can hold denatured clients soluble without transfer to BiP (PMID:31624144, PMID:41109348). DNAJB11 is a direct transcriptional target of XBP-1(S) during the UPR and plasma cell differentiation (PMID:17709512), and under ER stress it is secreted extracellularly where it substoichiometrically suppresses aggregation of misfolded proteins (PMID:25361606). The chaperone routes specific misfolded clients—including mutant glucocerebrosidase and Z-variant alpha-1-antitrypsin—toward ERAD (PMID:25126989, PMID:28419579). It is required for maturation and GPS cleavage of polycystin-1 in an SDF2/SDF2L1-dependent manner, and its loss causes PC1-dosage-dependent cystic kidney disease on the ADPKD spectrum (PMID:29706351, PMID:37332102, PMID:41109348). DNAJB11 additionally acquires a DNA-damage-responsive role through ATM-mediated phosphorylation at T188, which directs misfolded α-synuclein to the HSP70 system (PMID:41256008), and its abundance is controlled by RFFL-mediated ubiquitination and proteasomal degradation (PMID:40568870).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2000 High

    Establishing DNAJB11 as a bona fide ER luminal co-chaperone answered where and with which Hsp70 it acts, anchoring all later mechanism.

    Evidence Confocal localization, topology assays, and in vitro ATPase stimulation in a single study

    PMID:10827079

    Open questions at the time
    • Did not define which substrates it binds
    • Structural basis of BiP interaction not resolved
  2. 2004 High

    Showing ERdj3 binds unfolded substrates directly and dissociates before folding completes defined its order of action relative to BiP and its anti-aggregation role.

    Evidence In vitro ATPase-dead mutant, co-IP of unfolded clients, and pulse-chase kinetics

    PMID:15525676 PMID:15544163

    Open questions at the time
    • Substrate-binding residues not yet mapped
    • Mechanism of release not biochemically dissected
  3. 2007 High

    Identifying DNAJB11 as a direct XBP-1(S) target placed it within the UPR transcriptional program and secretory-cell biology.

    Evidence ChIP and EMSA in plasmacytoma and primary B cells with shRNA XBP-1 knockdown

    PMID:17709512

    Open questions at the time
    • Other UPR arms' contribution to induction not addressed
  4. 2009 High

    Mapping substrate-binding to domains I and II and showing F326-dependent multimerization explained how the chaperone recognizes clients and that self-assembly enables full activity.

    Evidence Structure-guided mutagenesis with in vitro and in vivo binding assays

    PMID:19090675

    Open questions at the time
    • Exact oligomeric architecture not resolved at this stage
  5. 2008 High

    Demonstrating that BiP ATP hydrolysis is required to release ERdj3 from substrate closed the loop on the handoff mechanism.

    Evidence BiP ATPase-cycle mutants and ERdj3 interaction mutants with in vitro release assays

    PMID:18923428

    Open questions at the time
    • Did not address stoichiometry of release per oligomer
  6. 2014 High

    Resolving that dimerization is required for binding while only one protomer must stimulate BiP for release refined the catalytic logic of the chaperone cycle.

    Evidence QPD mutant and heterodimer epistasis with pulse-chase kinetics

    PMID:25143379

    Open questions at the time
    • Higher-order tetramer not yet recognized in this work
  7. 2014 High

    Showing UPR-triggered secretion of ERdj3 extended its anti-aggregation function beyond the ER into the extracellular space.

    Evidence Secretion and co-secretion assays, aggregation inhibition, and proteotoxicity cell assays

    PMID:25361606

    Open questions at the time
    • Physiological extracellular substrates in vivo not defined
    • Regulation of the secretory decision unclear
  8. 2014 Medium

    Identifying DNAJB11 as a determinant of ERAD routing for disease-variant clients (mutant GCase, ZAAT) linked the chaperone to degradative triage decisions.

    Evidence IP-MS interaction, siRNA depletion, and pathway-redirection/degradation assays in patient-derived cells

    PMID:25126989 PMID:28419579

    Open questions at the time
    • Direct vs indirect ERAD targeting not fully separated
    • Single-lab characterization per client
  9. 2017 High

    Discovering the native tetramer (dimer of dimers) via domains II/III redefined the functional unit beyond canonical HSP40 dimers.

    Evidence EM structural modeling with domain-deletion mutagenesis and functional assays

    PMID:28655754

    Open questions at the time
    • High-resolution structure not obtained
    • Dynamics of oligomer interconversion unclear
  10. 2018 Medium

    Linking DNAJB11 loss to defective maturation of polycystin-1 and uromodulin connected its chaperone activity to human kidney disease clients.

    Evidence DNAJB11-null cells and affected human kidney tissue with trafficking/maturation assays

    PMID:29706351

    Open questions at the time
    • Causal in vivo mechanism not yet established
    • Whether PC1 or UMOD defect drives disease unresolved
  11. 2019 High

    Defining the ERdj3–SDF2/SDF2L1 complex explained ER retention and an enhanced, BiP-independent chaperone mode.

    Evidence In vitro reconstitution, aggregation suppression with denatured GST, co-IP, and localization analysis

    PMID:31624144

    Open questions at the time
    • Structural detail of the complex not resolved
    • Switch between tetramer and SDF2L1-bound state not defined
  12. 2023 High

    Mouse models established that DNAJB11 kidney disease arises from a PC1-specific GPS cleavage defect on the ADPKD spectrum, distinct from ADTKD/UPR mechanisms.

    Evidence Germline and conditional knockout mice, null cell lines, PC1 cleavage and UPR-marker assays

    PMID:37332102 PMID:39530576

    Open questions at the time
    • Molecular step of GPS cleavage facilitation not defined
    • Why PC1 is uniquely sensitive unclear
  13. 2024 Medium

    Identifying ATM phosphorylation of T188 revealed a DNA-damage-responsive, substrate-specific chaperone function for α-synuclein delivery to HSP70.

    Evidence Phosphoproteomics, T188 mutagenesis, co-chaperone delivery and neurite outgrowth assays

    PMID:41256008

    Open questions at the time
    • How an ER co-chaperone accesses cytoplasmic ATM signaling unclear
    • Single-lab finding
  14. 2025 High

    Validating SDF2/SDF2L1 as essential PC1-processing cofactors and RFFL as the degradative ligase tied the chaperone complex and its turnover to disease-relevant client processing.

    Evidence AP-MS, CRISPR knockouts with PC1 processing/rescue, label-free MS, and in vivo ubiquitination assays

    PMID:40568870 PMID:41109348

    Open questions at the time
    • RFFL regulation of DNAJB11 in physiological/disease contexts not established
    • Whether SDF2/SDF2L1 directly contact PC1 unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How DNAJB11 mechanistically facilitates the specific GPS autoproteolytic cleavage of polycystin-1, and how this is integrated with its tetramer/SDF2L1 states, remains unresolved.
  • No high-resolution structure of DNAJB11 with PC1 or SDF2L1
  • Molecular basis of PC1 client selectivity unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0044183 protein folding chaperone 5 GO:0098772 molecular function regulator activity 3 GO:0140096 catalytic activity, acting on a protein 3
Localization
GO:0005783 endoplasmic reticulum 3 GO:0005576 extracellular region 1
Pathway
R-HSA-1643685 Disease 5 R-HSA-392499 Metabolism of proteins 4 R-HSA-8953897 Cellular responses to stimuli 3
Partners
HSPA5RFFLSDF2SDF2L1SEC61A1
Complex memberships
ERdj3 homotetramer (dimer of dimers)ERdj3–SDF2–SDF2L1 complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2000 HEDJ/DNAJB11 is a luminal, membrane-associated ER-resident Hsp40 co-chaperone whose J domain interacts with the ER-associated Hsp70 BiP in an ATP-dependent manner and stimulates BiP's ATPase activity in vitro. Confocal microscopy for ER localization; protease susceptibility, glycosidase treatment, detergent solubility assays for luminal orientation; in vitro ATPase stimulation assay The Journal of biological chemistry High 10827079
2004 ERdj3 directly binds unfolded protein substrates (unassembled Ig heavy chains, unfolded light chains, VSV-G ts045 mutant) independently of BiP; an ERdj3 mutant unable to stimulate BiP's ATPase activity in vitro or bind BiP in vivo retains substrate binding, indicating ERdj3 contacts substrates directly rather than via BiP. ERdj3 binds substrates first and dissociates before folding is complete, whereas BiP remains bound longer, supporting a model where ERdj3 inhibits aggregation until BiP joins and then BiP-interaction triggers ERdj3 release. In vitro ATPase stimulation assay; co-immunoprecipitation; ERdj3 ATPase-stimulation-dead mutant; pulse-chase kinetics Molecular biology of the cell High 15525676
2004 ERdj3 is moderately induced by ER stressors; siRNA-mediated reduction of ERdj3 decreases ER stress tolerance in neuroblastoma cells, while overexpression of ERdj3 suppresses vero toxin-induced cell death. siRNA knockdown; ERdj3 overexpression by gene transfection; cell viability assays Cell stress & chaperones Medium 15544163
2005 Within the ER lumen, Shiga toxin interacts with HEDJ/ERdj3 and is found in a complex containing HEDJ and the translocon Sec61, suggesting ERdj3 participates in retrotranslocation of Shiga toxin from the ER to the cytosol. Sequential co-immunoprecipitation; confocal microscopy; genetic screen yielding dominant-negative HEDJ truncation Infection and immunity Medium 15784599
2007 XBP-1(S) directly binds the ERdj3 promoter in plasmacytoma cells and LPS-stimulated primary B cells, establishing ERdj3 as a direct transcriptional target of XBP-1(S) during plasma cell differentiation and the UPR. Chromatin immunoprecipitation (ChIP); shRNA-mediated XBP-1 knockdown; gel shift (EMSA) Journal of immunology High 17709512
2008 Release of ERdj3 from unfolded substrates requires a functional interaction with BiP including both direct physical contact and the ability to stimulate BiP's ATPase activity; BiP mutants defective at any step of the ATPase cycle fail to release ERdj3 from substrate, demonstrating ATP hydrolysis by BiP is mechanistically required for ERdj3 dissociation. ERdj3 and BiP interaction-disrupting mutants; BiP ATPase cycle mutants; co-immunoprecipitation; in vitro release assays The EMBO journal High 18923428
2009 ERdj3 binds unfolded substrates directly via conserved residues in domain I (homologous to peptide-binding site of yeast Ydj1) and domain II; domain II is critical for substrate binding and is not present in type II DnaJ family members. ERdj3 forms multimers in cells and the conserved C-terminal phenylalanine 326 is critical for self-assembly; mutation of F326A diminishes substrate binding, indicating multimerization is required for full substrate binding activity. Site-directed mutagenesis of conserved residues; in vitro and in vivo substrate binding assays; secondary structure prediction guided by Ydj1 crystal structure Biochemistry High 19090675
2010 The Salmonella T3SS effector SlrP targets ERdj3 domain II for interaction; SlrP co-localizes partially to the ER and interferes with ERdj3 binding to a denatured substrate, demonstrating SlrP modulates ERdj3 chaperone function in the ER. Co-immunoprecipitation with truncated ERdj3 constructs; confocal microscopy; subcellular fractionation; substrate binding competition assay The Journal of biological chemistry Medium 20335166
2010 ERdj3/DNAJB11 is a cellular binding partner and co-chaperone required for expression of the KSHV K1 oncoprotein; siRNA knockdown of ERdj3 dramatically reduces K1 protein levels and abolishes K1's anti-apoptotic function, identifying K1 as an ERdj3 client protein. Tandem affinity purification; bidirectional co-immunoprecipitation; siRNA knockdown; apoptosis assays Oncogene Medium 20418907
2011 ERdj3 directly binds unfolded (but not folded) cholera toxin CTA1 subunit via its A1(2) subdomain, masking solvent-exposed hydrophobic residues; expression of dominant-negative ERdj3 blocks CTA1 translocation into the cytosol, establishing ERdj3 as a host factor required for CT intoxication. Surface plasmon resonance binding assay; dominant-negative ERdj3 overexpression; cell-based translocation assay Infection and immunity Medium 21844235
2013 ERdj3 associates with a large complex including the translocon Sec61α in the ER; FRAP analysis shows overexpressed ERdj3 dramatically decreases BiP mobility in a client-dependent manner, while ERdj3 itself remains relatively immobile regardless of client levels, demonstrating ERdj3 regulates BiP engagement of client proteins and likely acts in ER subdomains enriched near the translocon. FRAP live-cell imaging; native gel electrophoresis; co-immunoprecipitation Journal of cell science Medium 23378021
2014 ERdj3 homodimers that cannot stimulate BiP ATPase (QPD mutants) accumulate on unfolded ER substrates due to impaired release rather than enhanced binding; dimerization is strictly required for substrate binding; heterodimers with one functional subunit show wild-type release rates, demonstrating only one protomer needs to stimulate BiP ATPase for ERdj3 release. QPD mutant co-expression; pulse-chase experiments; co-immunoprecipitation; heterodimer analysis The Journal of biological chemistry High 25143379
2014 ERdj3 promotes ERAD of mutant GCase (Gaucher's disease variants); depleting ERdj3 reduces mutant GCase degradation rate and redirects it to the calnexin pro-folding pathway, increasing GCase trafficking and lysosomal function. GCase immunoprecipitation followed by mass-spectrometry proteomics; siRNA ERdj3 depletion in patient-derived fibroblasts; GCase trafficking and activity assays Chemistry & biology Medium 25126989
2014 UPR activation upregulates and triggers secretion of ERdj3 into the extracellular space; secreted ERdj3 binds misfolded extracellular proteins, substoichiometrically inhibits their aggregation, and attenuates proteotoxicity of misfolded prion protein. ERdj3 can co-secrete with destabilized aggregation-prone clients as a stable complex when ER chaperoning is overwhelmed. ERdj3 secretion assays under UPR activation; co-secretion co-immunoprecipitation; aggregation inhibition assays; proteotoxicity cell-based assays The EMBO journal High 25361606
2017 ERdj3 promotes ERAD of Z-variant alpha-1-antitrypsin (ZAAT); depleting ERdj3 increases ZAAT degradation rate by redirecting ZAAT to the calreticulin-EDEM1 pathway followed by autophagosome formation. Co-immunoprecipitation; siRNA ERdj3 knockdown in hepatocytes; degradation rate assays; pathway marker analysis Journal of cellular biochemistry Medium 28419579
2017 ERdj3/DNAJB11 assembles as a native tetramer (dimer of dimers) rather than the dimer typical of other HSP40 co-chaperones; an EM structural model shows the tetramer involves inter-subunit interactions via domain II and domain III. Deletion of residues 175–190 within domain II renders ERdj3 a stable dimer with impaired substrate binding in the ER and extracellular space, reduced BiP interactions, and worsened ER stress-dependent client secretion and extracellular aggregation. Electron microscopy structural modeling; targeted domain deletion mutagenesis; co-immunoprecipitation; secretion and aggregation assays The EMBO journal High 28655754
2018 DNAJB11 loss impairs maturation and trafficking of the ADPKD protein polycystin-1 (PC1) and the ADTKD protein uromodulin (UMOD), establishing DNAJB11 as an ER co-chaperone required for processing of these disease-relevant clients. Characterization of DNAJB11-null cells; analysis of kidney samples from affected individuals; biochemical trafficking and maturation assays American journal of human genetics Medium 29706351
2019 SDF2L1 retains ERdj3 in the ER by forming a complex with ERdj3 and SDF2; the ERdj3 dimer incorporates two SDF2L1 molecules to form the ER-retained complex, whereas ERdj3 alone forms a homotetramer. The ERdj3–SDF2L1 complex shows higher chaperone activity than ERdj3 alone (suppressing ER protein aggregation without requiring substrate transfer to BiP) and maintains denatured GST in a soluble oligomeric state in vitro. Co-immunoprecipitation; in vitro aggregation suppression assay with denatured GST; intracellular localization analysis; in vitro reconstitution of ERdj3–SDF2L1 complex The Journal of biological chemistry High 31624144
2023 Dnajb11 loss in mice causes a profound defect in PC1 GPS cleavage with no effect on other cystoprotein processing assayed; conditional Dnajb11 loss in renal tubular epithelium produces PC1 dosage-dependent kidney cysts; Dnajb11 mouse models show no UPR activation or cyst-independent fibrosis, placing DNAJB11-kidney disease on the ADPKD spectrum via a PC1-dependent mechanism distinct from ADTKD pathogenesis. Germline and conditional mouse knockout alleles; Dnajb11-/- cell lines; PC1 C-terminal fragment cleavage assay; UPR activation markers Journal of the American Society of Nephrology High 37332102
2024 ATM kinase phosphorylates DNAJB11 at threonine 188 upon DNA double-strand breaks; this phosphorylation specifically facilitates delivery of misfolded α-synuclein (but not tau or transthyretin) to the HSP70 folding system, and loss of this response impairs neurite outgrowth. Large-scale proteomic analysis of ATM/ATR substrates; site-directed mutagenesis of T188; co-chaperone delivery assays; neurite outgrowth assay; correlation with transgenic PD mouse model and patient samples NAR molecular medicine Medium 41256008
2024 BiP/ERdj3 act as mechanical foldases under force (e.g., during co-translational folding through cellular tunnels), transitioning to holdase function in the absence of force; this force-regulated behavior is opposite to their cytoplasmic homologs DnaK/DnaJ, which act as holdases under force. Single-molecule force spectroscopy assays; comparison with DnaK/DnaJ homologs Protein science Medium 38864739
2024 Biallelic loss of Dnajb11 in mouse models causes cystic kidney disease and fibrosis; cysts originate predominantly from proximal tubules (distinct from classical ADPKD); impaired PC1 GPS cleavage is identified as the underlying molecular mechanism by proteomic analysis of Dnajb11- and Pkd1-deficient cells. Constitutive and conditional Dnajb11 knockout mouse models; Dnajb11-deficient renal epithelial cell lines; quantitative proteomics; PC1 cleavage assay FASEB journal High 39530576
2025 SDF2 and SDF2L1 are essential co-factors of DNAJB11 for PC1 processing; unbiased interaction proteomics identifies SDF2/SDF2L1 as strong DNAJB11 interactors; knockout of SDF2 and SDF2L1 together impairs PC1 processing, phenocopying DNAJB11 loss; DNAJB11 and SDF2/SDF2L1 show reciprocal interdependence of protein abundance. Unbiased interaction proteomics (AP-MS); CRISPR/Cas9 knockout cell lines; PC1 processing assays; complementation re-expression experiments The Journal of biological chemistry High 41109348
2025 The E3 ubiquitin ligase RFFL ubiquitinates DNAJB11 and promotes its degradation via the proteasomal pathway, identifying RFFL as a writer of ubiquitin on DNAJB11. Label-free quantitative mass spectrometry proteomics; CRISPR/Cas9 RFFL knockout; stable RFFL re-expression; in vivo ubiquitination assays Journal of proteome research Medium 40568870

Source papers

Stage 0 corpus · 31 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American journal of human genetics 237 29706351
2004 ERdj3, a stress-inducible endoplasmic reticulum DnaJ homologue, serves as a cofactor for BiP's interactions with unfolded substrates. Molecular biology of the cell 166 15525676
2014 Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis. The EMBO journal 105 25361606
2000 HEDJ, an Hsp40 co-chaperone localized to the endoplasmic reticulum of human cells. The Journal of biological chemistry 94 10827079
2005 Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infection and immunity 93 15784599
2008 Regulated release of ERdj3 from unfolded proteins by BiP. The EMBO journal 68 18923428
2010 The Salmonella type III secretion effector, salmonella leucine-rich repeat protein (SlrP), targets the human chaperone ERdj3. The Journal of biological chemistry 67 20335166
2009 ERdj3, a luminal ER DnaJ homologue, binds directly to unfolded proteins in the mammalian ER: identification of critical residues. Biochemistry 63 19090675
2014 ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease. Chemistry & biology 62 25126989
2010 Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. Oncogene 55 20418907
2013 ERdj3 regulates BiP occupancy in living cells. Journal of cell science 44 23378021
2017 The endoplasmic reticulum HSP40 co-chaperone ERdj3/DNAJB11 assembles and functions as a tetramer. The EMBO journal 43 28655754
2019 SDF2-like protein 1 (SDF2L1) regulates the endoplasmic reticulum localization and chaperone activity of ERdj3 protein. The Journal of biological chemistry 28 31624144
2007 Identification of ERdj3 and OBF-1/BOB-1/OCA-B as direct targets of XBP-1 during plasma cell differentiation. Journal of immunology (Baltimore, Md. : 1950) 26 17709512
2022 Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathway. Cellular & molecular biology letters 21 36209075
2017 Erdj3 Has an Essential Role for Z Variant Alpha-1-Antitrypsin Degradation. Journal of cellular biochemistry 21 28419579
2004 Localization and function in endoplasmic reticulum stress tolerance of ERdj3, a new member of Hsp40 family protein. Cell stress & chaperones 21 15544163
2011 Structural and functional interactions between the cholera toxin A1 subunit and ERdj3/HEDJ, a chaperone of the endoplasmic reticulum. Infection and immunity 19 21844235
2020 Bi-allelic pathogenic variations in DNAJB11 cause Ivemark II syndrome, a renal-hepatic-pancreatic dysplasia. Kidney international 17 33129895
2014 Dissection of structural and functional requirements that underlie the interaction of ERdj3 protein with substrates in the endoplasmic reticulum. The Journal of biological chemistry 17 25143379
2018 The endoplasmic reticulum co-chaperone ERdj3/DNAJB11 promotes hepatocellular carcinoma progression through suppressing AATZ degradation. Future oncology (London, England) 13 29992839
2022 More dissimilarities than affinities between DNAJB11-PKD and ADPKD. Clinical kidney journal 12 35664268
2023 Dnajb11-Kidney Disease Develops from Reduced Polycystin-1 Dosage but not Unfolded Protein Response in Mice. Journal of the American Society of Nephrology : JASN 7 37332102
2024 Force-regulated chaperone activity of BiP/ERdj3 is opposite to their homologs DnaK/DnaJ. Protein science : a publication of the Protein Society 5 38864739
2024 The role of the co-chaperone DNAJB11 in polycystic kidney disease: Molecular mechanisms and cellular origin of cyst formation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 5 39530576
2024 ATM-mediated co-chaperone DNAJB11 phosphorylation facilitates α-synuclein folding upon DNA double-stranded breaks. NAR molecular medicine 4 41256008
2023 DNAJB11 Mutation in ADPKD Patients: Clinical Characteristics in a Monocentric Cohort. Genes 3 38275584
2025 Quantitative Proteomic Analysis Reveals JMJD6 and DNAJB11 as Endogenous Substrates of E3 Ligase RFFL. Journal of proteome research 1 40568870
2023 Atypical ADPKD Due to a DNAJB11 Pathogenic Variant: An Educational Case Report. Canadian journal of kidney health and disease 1 37867501
2017 [Expression and clinical significance of DNAJB11 in epithelial ovarian cancer]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 1 28752709
2025 SDF2 and SDF2L1 are essential co-factors of DNAJB11 for Polycystin-1 processing. The Journal of biological chemistry 0 41109348

Missed literature

Know a paper Affinage missed for DNAJB11? Flag it for the maintainers and the community.

No submissions yet.